Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny - 2UN mission says no evidence Hezbollah rearming in southern Lebanon
- 3Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- 4The Best Competitors of the 21st Hundred years
- 5Should you get an RSV vaccine this fall? What to know and where to get a shot
- 10 Delectable Specialty Mixed drinks
- Manual for Picking the Ideal Wine Matching
- Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- Kennedy approves adding two rare disorders to newborn screenings
- New law puts familiar drinks, creams and gummies in legal limbo
- Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- Robert Pattinson claims he's a pathological liar. What 'The Drama' star has said about his 'shtick'
- Putting resources into Yourself: Self-awareness Techniques
- Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
